Paris, France and Camberley, UK – 2 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”).
The Liquidity Agreement is governed by French law and is further summarized in the ‘notes for editors’ section below.
During the period from 1 October to 31 October 2020, Invest Securities purchased 34,371 ordinary shares at a maximum price of €12.73 and a minimum price of €6.75 and sold 37,750 ordinary shares at a maximum price of €12.83 and a minimum price of €6.30 under the Liquidity Agreement. The total number of ordinary shares in the Company, which are held in treasury as at close of business on 31 October 2020, is 4,021.
Total Voting Rights
The total number of ordinary shares in the Company is 70,626,248. This figure may be used by shareholders as the denominator for calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company pursuant to Article L. 223-7 of the French Commercial Code and the Company’s Articles. The Company is not subject to the disclosure guidance and transparency rules made by the Financial Conduct Authority under Part VI of FSMA.
For further information, please refer to www.novacyt.com
About Novacyt Group
The Novacyt Group is an international diagnostics business generating an increasing portfolio of in vitro and molecular diagnostic tests. Its core strengths lie in diagnostics product development, commercialisation, contract design and manufacturing. The Company’s lead business units comprise of Primerdesign and Lab21 Products, supplying an extensive range of high-quality assays and reagents worldwide. The Group directly serves microbiology, haematology and serology markets as do its global partners, which include major corporates.
